南方财经5月12日电，天眼查App显示，近日，复星医药（600196）发生工商变更，吴以芳卸任法定代表人、董事长，由陈玉卿接任，同时部分高管发生变更。上海复星医药（集团）股份有限公司成立于1995年5月，注册资本约26.7亿人民币，经营范围包括经营本企业自产产品及相关技术的出口业务，经营本企业生产、科研所需的原辅材料、机械设备、仪器仪表、零配件及相关技术的进口业务等，由上海复星高科技（集团）有限公司、HKSCCNOMINEESLIMITED、香港中央结算有限公司等共同持股。据媒体此前报道，复星医药发布公告称，吴以芳不再担任复星医药执行董事、董事长职务，改任复星医药非执行董事，陈玉卿担任复星医药董事长、执行董事。

（文章来源：南方财经网）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.